Fingolimod (FTY720, 2-amino-2-propane-1,3-diol hydrochloride) is a remarkably efficient immunosuppressive drug that was recently approved as the first oral treatment for multiple sclerosis. Fingolimod prevents lymphocyte egress from lymph nodes by targeting 4 of 5 sphingosine-1-phosphate receptors. 1 Two phase 3 trials showed that fingolimod significantly reduced multiple sclerosis disease progression compared with placebo or standard treatment. 2, 3 However, both trials concluded that longer studies were required to assess possible long-term risks. 2, 3 Reports from studies in mice and humans strongly support a crucial role of lymphocytes and adaptive immunity in both preventing cancer and fighting established tumors in a process called cancer immunosurveillance. 4, 5 In transplant recipients, lifelong immunosuppressive treatment is associated with an increased risk of cancer. 6 We investigated the effect of fingolimod on cancer immunosurveillance mediated by tumor-specific CD4 ϩ T cells in mouse models for myeloma and B-cell lymphoma. We used severe combined immunodeficient (SCID) mice made transgenic for a T cell receptor (TCR) that recognizes a tumor-specific idiotypic (Id) antigen that is secreted by MOPC315 myeloma and F9 B-cell lymphoma. 7,8 The For personal use only. on April 20, 2017. by guest www.bloodjournal.org From Id-specific TCR-transgenic SCID mice are resistant against subcutaneous challenge with MOPC315 and F9 cells. The protection is Id-specific, CD4 ϩ T cell-mediated and does not require the presence of B cells and CD8 ϩ T cells. 7, 8 On cancer cell inoculation, Id-specific CD4 ϩ T cells first become activated in the draining lymph nodes where they acquire a T helper type 1 (Th1) phenotype. Id-specific Th1 cells then migrate to the incipient tumor site and secrete IFN-␥, resulting in local activation of macrophages which become tumoricidal and eradicate the cancer cells. 9, 10 Id-specific TCR-transgenic SCID and control nontransgenic SCID mice were inoculated with cancer cells and treated daily with fingolimod or vehicle only. Fingolimod efficiently blocked rejection of both MOPC315 myeloma and F9 B-cell lymphoma by TCR-transgenic mice ( Figure 1A-B) . Fingolimod had no effect on the survival of control nontransgenic SCID mice inoculated with MOPC315 ( Figure 1C ). Fingolimod did not block activation of tumor-specific CD4 ϩ T cells in the draining lymph nodes, as defined by up-regulation of CD69 ( Figure 1D ). In contrast, fingolimod strongly inhibited migration of tumor-specific CD4 ϩ T cells to the incipient tumor site ( Figure 1E ). Furthermore, fingolimod prevented Th1-mediated activation of tumor-infiltrating macrophages, as measured by up-regulation of surface major histocompatibility (MHC) class II molecules. In fact, in TCRtransgenic mice treated with fingolimod, tumor-infiltrating macrophages had surface MHC class II levels that were as low as those of macrophages from T cell-deficient SCID mice ( Figure 1F) . Thus, the data strongly suggest that fingolimod blocks immunosurveillance of B-cell cancers by suppressing migration of tumor-specific Th1 cells from lymph nodes to the incipient tumor site, thereby preventing Th1-mediated activation of tumoricidal macrophages.
To the editor:
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice
Fingolimod (FTY720, 2-amino-2-propane-1,3-diol hydrochloride) is a remarkably efficient immunosuppressive drug that was recently approved as the first oral treatment for multiple sclerosis. Fingolimod prevents lymphocyte egress from lymph nodes by targeting 4 of 5 sphingosine-1-phosphate receptors. 1 Two phase 3 trials showed that fingolimod significantly reduced multiple sclerosis disease progression compared with placebo or standard treatment. 2, 3 However, both trials concluded that longer studies were required to assess possible long-term risks. 2, 3 Reports from studies in mice and humans strongly support a crucial role of lymphocytes and adaptive immunity in both preventing cancer and fighting established tumors in a process called cancer immunosurveillance. 4, 5 In transplant recipients, lifelong immunosuppressive treatment is associated with an increased risk of cancer. 6 We investigated the effect of fingolimod on cancer immunosurveillance mediated by tumor-specific CD4 ϩ T cells in mouse models for myeloma and B-cell lymphoma. We used severe combined immunodeficient (SCID) mice made transgenic for a T cell receptor (TCR) that recognizes a tumor-specific idiotypic (Id) antigen that is secreted by MOPC315 myeloma and F9 B-cell lymphoma. 7, 8 The Id-specific TCR-transgenic SCID mice are resistant against subcutaneous challenge with MOPC315 and F9 cells. The protection is Id-specific, CD4 ϩ T cell-mediated and does not require the presence of B cells and CD8 ϩ T cells. 7, 8 On cancer cell inoculation, Id-specific CD4 ϩ T cells first become activated in the draining lymph nodes where they acquire a T helper type 1 (Th1) phenotype. Id-specific Th1 cells then migrate to the incipient tumor site and secrete IFN-␥, resulting in local activation of macrophages which become tumoricidal and eradicate the cancer cells. 9, 10 Id-specific TCR-transgenic SCID and control nontransgenic SCID mice were inoculated with cancer cells and treated daily with fingolimod or vehicle only. Fingolimod efficiently blocked rejection of both MOPC315 myeloma and F9 B-cell lymphoma by TCR-transgenic mice ( Figure 1A-B) . Fingolimod had no effect on the survival of control nontransgenic SCID mice inoculated with MOPC315 ( Figure 1C ). Fingolimod did not block activation of tumor-specific CD4 ϩ T cells in the draining lymph nodes, as defined by up-regulation of CD69 ( Figure 1D ). In contrast, fingolimod strongly inhibited migration of tumor-specific CD4 ϩ T cells to the incipient tumor site ( Figure 1E ). Furthermore, fingolimod prevented Th1-mediated activation of tumor-infiltrating macrophages, as measured by up-regulation of surface major histocompatibility (MHC) class II molecules. In fact, in TCRtransgenic mice treated with fingolimod, tumor-infiltrating macrophages had surface MHC class II levels that were as low as those of macrophages from T cell-deficient SCID mice ( Figure 1F) . Thus, the data strongly suggest that fingolimod blocks immunosurveillance of B-cell cancers by suppressing migration of tumor-specific Th1 cells from lymph nodes to the incipient tumor site, thereby preventing Th1-mediated activation of tumoricidal macrophages.
In summary, fingolimod is a strong immunosuppressive drug which blocks immunosurveillance of myeloma and B-cell lymphoma by CD4 ϩ T cells in experimental mouse models, resulting in cancer development. Further studies are required to determine the effect of fingolimod on other immune cells involved in cancer immunosurveillance such as CD8 ϩ T cells and NK cells. 4 In our experiments, mice were treated with rather high doses of fingolimod (1-2 mg/kg bodyweight/d) to efficiently block sphingosine-1-phosphate receptors. Patients receive much lower doses (0.5-1.25 mg/d) but for longer time periods (years). Therefore, our findings cannot be directly translated to patients. However, the data suggest that long-term treatment with fingolimod may potentially lead to increased risk of cancer in humans.
CEBPE activation in PML-RARA cells by arsenic
In a recent perspective, Ablain and de The challenged the classic model of acute promyelocytic leukemia (APL), whereby differentiation-impairment in lineage-committed progenitors causes self-renewal, and instead proposed that APL arises from deregulation of stem cell self-renewal pathways in leukemia initiating cells, with the curative potential of arsenic (As 2 O 3 ) relating to abrogation of these pathways. 1 However, differentiation syndrome occurs at a similar rate with As 2 O 3 as with all-trans retinoic acid (ATRA), and furthermore, disseminated intravascular coagulation, the potentially fatal complication frequently triggered by cytotoxic treatment, is not typical. 2 Hence, clinical experience suggests that important actions of As 2 O 3 include terminating APL proliferation by differentiation. To evaluate this further, the APL cell line NB4 was treated with low concentrations of As 2 O 3 which do not induce early apoptosis 3 ( Figure 1A ; supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top
